China bladder cancer market is estimated to grow modestly at a CAGR of around 10.1% during the forecast period. The country has a strong healthcare industry and is continuously developing medical facilities and research centers to improve the industry further. Bladder cancer is one of the major cancers diagnosed in the elderly population of the country. The growing prevalence of bladder cancer in the country is attributed to growth in the aging population and a rapid increase in the number of smokers. Cancer is one of the leading causes of mortality in China. According to WHO, China has reported a total of 82,270 new cases of bladder cancer in 2018 out of which 38,208 cases resulted in mortality. As per the organization, China accounts for 222,292 bladder cancer patients in the last 5 years. Due to increasing industrialization in the country, harmful chemicals are being ejected into the atmosphere and chemical exposure is one of the major causes of bladder cancer. Therefore, with rapid industrialization in the country, China is estimated to contribute substantially to the global bladder cancer market during the forecast period.
A full report of China Bladder Cancer Market is available at: https://www.omrglobal.com/industry-reports/china-bladder-cancer-market
China bladder cancer market is segmented into cancer type, diagnosis, and treatment. Based on cancer type, the market is segmented into transitional cell bladder cancer/ urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma, and other rare types (sarcomas, carcinoma in situ). Based on the diagnosis, the market is segmented into cystoscopy, biopsy, urinalysis, urine cytology, intravenous pyelogram (IVP), and others. Based on treatment, the market is segmented into chemotherapy, immunotherapy, radiation therapy, surgery, and other treatment which include targeted therapy.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/china-bladder-cancer-market
The companies which are contributing to the growth of China bladder cancer market include AstraZeneca PLC, Bristol-Myers Squibb, Co., Eli Lilly & Co., GlaxoSmithKline PLC, and Pfizer, Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.
China Bladder Cancer Market- Segmentation
By Cancer type
- Transitional Cell Bladder Cancer/ Urothelial Carcinoma
- Squamous Cell Bladder Cancer
- Adenocarcinoma
- Other Rare Types (Sarcomas, Carcinoma in Situ)
By Diagnosis Method
- Cystoscopy
- Biopsy
- Urinalysis
- Urine Cytology
- Intravenous Pyelogram (Ivp)
- Other
By Therapy
- Chemotherapy
- Immunotherapy
- Radiation Therapy
- Surgery
- Other
